Trump has begun another trade war. Here's a timeline of how we got here
Canada's leader laments lost friendship with US in town that sheltered stranded Americans after 9/11
Chinese EV giant BYD's fourth-quarter profit leaps 73%
You're an American in another land? Prepare to talk about the why and how of Trump 2.0
Chalk talk: Star power, top teams and No. 5 seeds headline the women's March Madness Sweet 16
Purdue returns to Sweet 16 with 76-62 win over McNeese in March Madness
By Rishika Sadam
HYDERABAD (Reuters) - Danish drugmaker Novo Nordisk is looking at an early launch of its blockbuster weight-loss drug Wegovy in India to better compete with rival Eli Lilly in the populous nation, two sources familiar with the plans told Reuters.
Novo, which had earlier planned for a 2026 launch of the drug, is now looking to begin selling Wegovy in India "this year, probably in the next few months," sources told Reuters on condition of anonymity as they were not authorized to talk to the media.
"Novo's also assessing the stock situation to handle the demand in India. They want to avoid any shortage issues," one of the sources said.
The company's accelerated plan follows U.S. rival Eli Lilly's launch of its diabetes and obesity drug Mounjaro in India last month.
Reuters reported earlier that Novo's India team had been pushing the global headquarters for an early Wegovy launch.
Novo and Lilly have seen skyrocketing global demand for their innovative weight-loss drugs, with investor interest also boosting the drugmakers to among the world's most valuable companies.
The competing drugs belong to a class of therapies known as GLP-1 receptor agonists that help control blood sugar and slow digestion, making people feel fuller for longer.
Semaglutide, the active ingredient in Novo's Wegovy and diabetes medicine Ozempic, goes off patent in India in 2026, paving way for generic drugmakers to produce cheaper versions of the drugs.
Local drugmakers such as Sun Pharma, Cipla and Dr Reddy's have been racing to build up supplies with an eye on a share of a global market analysts have estimated could be worth $150 billion annually in the next decade.
Novo declined to comment on Monday, but previously said Wegovy has been approved in India. It did not have a confirmed date for the medicine's India launch at the time.
"Novo also thinks that its brand names Ozempic, Wegovy have better penetration in the market, which would give them an edge," the other source said.
Still, Novo would need to offer the drug at a competitive price to Lilly's once-weekly Mounjaro injection, which costs about $50 for a 5 milligram vial, and $40 for a 2.5 mg vial, the lowest doses.
(Reporting by Rishika Sadam in Hyderabad and Maggie Fick in London; Editing by Bill Berkrot)
